Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening microangiopathy, frequently causing kidney failure. Inhibition of the terminal complement complex with eculizumab is the only licensed treatment but mostly requires long-term administration and risks severe side effect...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Nephrol
Main Authors: Klämbt, Verena, Gimpel, Charlotte, Bald, Martin, Gerken, Christopher, Billing, Heiko, Loos, Sebastian, Hansen, Matthias, König, Jens, Vinke, Tobias, Montoya, Carmen, Lange-Sperandio, Bärbel, Kirschstein, Martin, Hennies, Imke, Pohl, Martin, Häffner, Karsten
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7815604/
https://ncbi.nlm.nih.gov/pubmed/32715379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-020-04714-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados